Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12607000572460
Ethics application status
Approved
Date submitted
5/11/2007
Date registered
6/11/2007
Date last updated
6/11/2007
Type of registration
Prospectively registered
Titles & IDs
Public title
Nicotine replacement thrapy as a secondary prevention strategy in post-operative coronary bypass patients
Query!
Scientific title
An examination of the effectiveness of transdermal nicotine replacment therapy as a secondary prevention strategy in patients admitted to hospital for coronary artery bypass grafting
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
NRT Trial
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
smoking
2526
0
Query!
Condition category
Condition code
Cardiovascular
2622
2622
0
0
Query!
Coronary heart disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Transdermal nicotine patch. 10 week programe of nicotine patch starting at 21mg for 6 weeks, 14 mg for 2 weeks, 7mg of 2 weeks.
Transdermal nicotine patch contains nicotine which is absorbed through the skin.
Query!
Intervention code [1]
2255
0
Treatment: Drugs
Query!
Comparator / control treatment
no treatment
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
3533
0
6 month abstinence rates,
Query!
Assessment method [1]
3533
0
Query!
Timepoint [1]
3533
0
6 month following bypass surgery & initiation of intervention
Query!
Secondary outcome [1]
5913
0
withdrawal symptoms
Query!
Assessment method [1]
5913
0
Query!
Timepoint [1]
5913
0
1 wk, 4 wks, 3 mths, 6 mths
Query!
Secondary outcome [2]
5914
0
adverse effects
Query!
Assessment method [2]
5914
0
Query!
Timepoint [2]
5914
0
1 wk, 4 wks, 3 mths, 6 mths
Query!
Eligibility
Key inclusion criteria
Current smoker, admitted to hospital for coronary artery bypass grafting.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
N/A
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Recent myocardial infarction ( within 3mths prior to recruitment). Suffer from unstable angina. Has suffered a cerebrovascular accident (CVA). Hypersensitivity to nicotine, menthol or adhesive tapes. History of substance abuse in the previous 12mts.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Potential participants will be assessed by the pre-operative cardiac education nurse for inclusion or exclusion into the study. Following identification for inclusion the pre-op education nurse will randomly remove an envelope from a box provided, this envelope will have an ID Number printed on it which will become the participants ID No for the study. Participants will be required to complete the questionnaires inside the envelope and at various stages throughout the study process . Participants will be provided with an information sheet which outlines the studies purpose and aims. Participants will be required to sign a consent form in the presence of the pre-op education nurse who will also witness this form. ID numbers will be used on all documentation and drugs thorughout the trial process to assure anonymity and confidentiality of data. The participant (if in the intervention group) will begin drug (NRT) treatment following surgery and transfer to the cardiac step-down unit (approximately 24 hrs or more following surgery).
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation of participant ID numbers will be achieved by a computer generated randomisation sequence using Microsoft Excel. The envelopes that contain the questionnaires will have the ID number printed on the exterior. These envelopes will be placed within a box for the cardiac pre-op education nurse to randomly remove during recruitment. The ID number of which has already been randomised to either the control or intervention group.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/12/2007
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment postcode(s) [1]
319
0
5000
Query!
Funding & Sponsors
Funding source category [1]
2767
0
University
Query!
Name [1]
2767
0
GlaxoSmithKline
Query!
Address [1]
2767
0
GlaxoSmithKline
Consumer Healthcare
82 Hughes Avenue
Ermington
NSW 2115
Query!
Country [1]
2767
0
Australia
Query!
Primary sponsor type
University
Query!
Name
University of Adelaide
Query!
Address
Discipline of General Practice
North Terace
Adelaide
South Australia 5005
Query!
Country
Australia
Query!
Secondary sponsor category [1]
2500
0
Commercial sector/Industry
Query!
Name [1]
2500
0
GlaxoSmithKline
Query!
Address [1]
2500
0
GlaxoSmithKline
Consumer Healthcare
82 Hughes Avenue
Ermington
NSW 2115
Query!
Country [1]
2500
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
4689
0
Royal Adelaide Hospital Human Research Ethics Committee
Query!
Ethics committee address [1]
4689
0
Royal Adelaide Hospital North Terrace Adelaide South Australia 5000
Query!
Ethics committee country [1]
4689
0
Australia
Query!
Date submitted for ethics approval [1]
4689
0
Query!
Approval date [1]
4689
0
24/09/2007
Query!
Ethics approval number [1]
4689
0
070911
Query!
Summary
Brief summary
The purpose of this study is to examine the post operative efficacy and safety of NRT initiated in patients admitted to hospital for coronary artery bypass surgery. We hypothesise that commencing NRT in the immediate post operative phase will be well tolerated by patients, lead to fewer withdrawal symptoms and greater quit rates at 6 months. This pilot randomised control trial is expected to validate the feasibility of conducting a larger scale multi-centre trial that will generate evidence to support the use of NRT as an inpatient initiated secondary prevention strategy in post-operative bypass patients.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
28162
0
Query!
Address
28162
0
Query!
Country
28162
0
Query!
Phone
28162
0
Query!
Fax
28162
0
Query!
Email
28162
0
Query!
Contact person for public queries
Name
11319
0
Fiona May
Query!
Address
11319
0
Discipline of General Practice
University of Adelaide
North Terrace
Adelaide
South Australia 5005
Query!
Country
11319
0
Australia
Query!
Phone
11319
0
0413 683 693
Query!
Fax
11319
0
08 8303 3511
Query!
Email
11319
0
[email protected]
Query!
Contact person for scientific queries
Name
2247
0
Fiona May
Query!
Address
2247
0
Discipline of General Practice
North Terrace
Adelaide
South Australia 5005
Query!
Country
2247
0
Australia
Query!
Phone
2247
0
08 8303 3460
Query!
Fax
2247
0
08 8303 3511
Query!
Email
2247
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF